PRVB · Provention Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $756.0K | $746.0K | $580.0K | - | $678.0K | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $16.34M | $16.58M | $17.36M | - | $17.72M | $16.97M | $19.69M | - | $21.66M |
| SG&A | - | $13.49M | $14.00M | $12.31M | - | $10.03M | $13.21M | $12.78M | - | $9.75M |
| Total Operating Expenses | - | $29.83M | $30.58M | $29.66M | - | $27.75M | $30.17M | $32.47M | - | $31.41M |
| D&A | - | $100.0K | $200.0K | $137.0K | - | $100.0K | $100.0K | $73.0K | - | - |
| Operating Income | - | ($29.08M) | ($29.83M) | ($29.08M) | - | ($27.08M) | ($30.17M) | ($32.47M) | - | ($31.41M) |
| Interest Expense | - | $255.0K | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | ($7.06M) | - | - | ($1.00M) | - | - | - |
| Net Income | - | ($28.63M) | ($29.69M) | ($21.97M) | - | ($27.02M) | ($29.14M) | ($32.44M) | - | ($31.30M) |
| EPS - Basic | - | ($0.43) | ($0.46) | ($0.52) | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $44.04M | $102.38M | $57.88M | $74.91M | $78.19M | $139.34M | $151.78M | $180.36M | $102.29M | $118.44M |
| Accounts Receivable | $1.36M | - | - | - | - | - | - | - | - | - |
| Inventory | $1.23M | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $6.76M | $3.79M | $5.66M | $7.24M | $3.55M | $3.63M | $3.87M | $8.28M | $7.57M | $7.11M |
| Current Assets | $174.65M | $190.43M | $90.31M | $91.79M | $101.10M | $155.26M | $180.59M | $211.65M | $126.55M | $151.33M |
| Total Assets | $236.86M | $193.91M | $104.35M | $122.46M | $135.62M | $157.88M | $183.31M | $213.79M | $128.52M | $151.80M |
| Current Liabilities | $90.39M | $25.12M | $25.15M | $27.05M | $22.79M | $20.81M | $24.63M | $26.75M | $16.73M | $16.40M |
| Long-term Debt | $23.47M | $23.30M | - | - | - | - | - | - | - | - |
| Total Liabilities | $115.01M | $49.14M | $25.67M | $28.25M | $24.89M | $23.76M | $25.29M | $29.92M | $17.45M | - |
| Stockholders' Equity | $121.85M | $144.77M | $78.68M | $94.21M | $110.73M | $134.11M | $158.02M | $183.87M | $111.07M | $135.40M |
| Retained Earnings | ($405.64M) | ($372.36M) | ($343.73M) | ($314.04M) | ($292.07M) | ($266.25M) | ($239.22M) | ($210.08M) | ($177.64M) | ($145.07M) |
Cash Flow
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($15.03M) | - | - | - | ($16.49M) | - | - |
| Investing Cash Flow | - | - | - | $9.60M | - | - | - | ($7.83M) | - | - |
| Financing Cash Flow | - | - | - | $2.15M | - | - | - | $102.38M | - | - |
| CapEx | - | - | - | - | - | - | - | $250.0K | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | ($16.74M) | - | - |
Ratios
| Metric | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -3846.3% | -3999.1% | -5014.0% | - | -3993.7% | - | - | - | - |
| EBITDA margin | - | -3833.1% | -3972.3% | -4990.3% | - | -3978.9% | - | - | - | - |
| Net margin | - | -3787.4% | -3979.5% | -3787.6% | - | -3985.5% | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | 0.52 | - | - |
| R&D / Revenue | - | 2161.2% | 2222.1% | 2992.2% | - | 2614.2% | - | - | - | - |
| SG&A / Revenue | - | 1785.1% | 1876.9% | 2121.7% | - | 1479.5% | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -14.8% | -28.4% | -17.9% | - | -17.1% | -15.9% | -15.2% | - | -20.6% |
| Return on equity | - | -19.8% | -37.7% | -23.3% | - | -20.1% | -18.4% | -17.6% | - | -23.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.93 | 7.58 | 3.59 | 3.39 | 4.44 | 7.46 | 7.33 | 7.91 | 7.56 | 9.23 |
| Quick ratio | 1.92 | 7.58 | 3.59 | 3.39 | 4.44 | 7.46 | 7.33 | 7.91 | 7.56 | 9.23 |
| Cash ratio | 0.49 | 4.08 | 2.30 | 2.77 | 3.43 | 6.70 | 6.16 | 6.74 | 6.11 | 7.22 |
| Leverage | ||||||||||
| Debt / Equity | 0.19 | 0.16 | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.10 | 0.12 | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -114.0x | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.94 | 1.34 | 1.33 | 1.30 | 1.22 | 1.18 | 1.16 | 1.16 | 1.16 | 1.12 |
| Liabilities / Assets | 0.49 | 0.25 | 0.25 | 0.23 | 0.18 | 0.15 | 0.14 | 0.14 | 0.14 | - |
| Efficiency | ||||||||||
| Asset turnover | - | 0.00 | 0.01 | 0.00 | - | 0.00 | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 11.5% | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -7.4% | 1.1% | 10.4% | - | 13.8% | -32.4% | -152.4% | - | -214.9% |
| Net income growth (YoY) | - | -6.0% | -1.9% | 32.3% | - | 13.7% | -31.7% | -157.8% | - | -220.4% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 10.0% | 7.9% | -50.2% | -48.8% | -0.3% | -0.9% | -3.5% | 158.2% | 35.2% | 48.1% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Provention Bio against the 5 most active filers in the same SIC group.